Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 23;12(5):1195.
doi: 10.3390/polym12051195.

Positively Charged Polymers as Promising Devices against Multidrug Resistant Gram-Negative Bacteria: A Review

Affiliations
Review

Positively Charged Polymers as Promising Devices against Multidrug Resistant Gram-Negative Bacteria: A Review

Silvana Alfei et al. Polymers (Basel). .

Abstract

Antibiotic resistance has increased markedly in Gram-negative bacteria, causing severe infections intractable with traditional drugs and amplifying mortality and healthcare costs. Consequently, to find novel antimicrobial compounds, active on multidrug resistant bacteria, is mandatory. In this regard, cationic antimicrobial peptides (CAMPs)-able to kill pathogens on contact-could represent an appealing solution. However, low selectivity, hemolytic toxicity and cost of manufacturing, hamper their massive clinical application. In the recent years-starting from CAMPs as template molecules-less toxic and lower-cost synthetic mimics of CAMPs, including cationic peptides, polymers and dendrimers, have been developed. Although the pending issue of hemolytic toxicity and biodegradability is still left not completely solved, cationic antimicrobial polymers (CAPs), compared to small drug molecules, thanks to their high molecular weight, own appreciable selectivity, reduced toxicity toward eukaryotic cells, more long-term activity, stability and non-volatility. With this background, an updated overview concerning the main manufactured types of CAPs, active on Gram-negative bacteria, is herein reported, including synthetic procedure and action's mechanism. Information about their structures, antibacterial activity, advantages and drawbacks, was reported in the form of tables, which allow faster consultation and quicker learning concerning current CAPs state of the art, in order not to retrace reviews already available.

Keywords: Gram-negative bacteria; antibiotic resistance; hemolytic cytotoxicity; membrane disruption; positively charged polymers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structure of colistin.
Figure 2
Figure 2
Number of publications as a function of time that contain the phrase “antimicrobial polymer” via Scopus. These data include the cationic antimicrobial polymers literature (the scope of this review).
Figure 3
Figure 3
Examples of cationic antimicrobial peptides (CAMPs) not susceptible to develop resistance: (a) Structure of tachyplesin II; (b) structure of cecropin P1.
Figure 4
Figure 4
Schematic representation of the structure of the cell wall of Gram-negative bacteria.
Figure 5
Figure 5
Quaternized chitosan derivatives permanently cationic: (a) Chitosan phosphonium salt; (b) o-quaternary chitosan ammonium salts. R: –CH2Ph (BNQAS–CS); –C12H25 (C12QAS–CS); – C14H29 (C14QAS–CS); – C16H33 (C16QAS–CS); – C18H37 (C18QAS–CS); X: Cl, Br.

References

    1. Pouch S.M., Kubin C.J., Satlin M.J., Tsapepas D.S., Lee J.R., Dube G., Pereira M.R. Epidemiology and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteriuria in kidney transplant recipients. Transpl. Infect. Dis. 2015;17:800–809. doi: 10.1111/tid.12450. - DOI - PMC - PubMed
    1. Thaden J.T., Li Y., Run F., Maskarinec S.A., Hill-Rorie J.M., Wanda L.C., Reed S.D., Fowler V.G., Jr. Increased Costs Associated with Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Bacteria Are Due Primarily to Patients with Hospital-Acquired Infections. Antimicrob. Agents Chemother. 2017;61:e01709-01716. doi: 10.1128/AAC.01709-16. - DOI - PMC - PubMed
    1. Peleg A.Y., Hooper D.C. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. 2010;362:1804–1813. doi: 10.1056/NEJMra0904124. - DOI - PMC - PubMed
    1. WHO . Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline. WHO; Geneva, Switzerland: 2019.
    1. WHO . Antibacterial Agents in Preclinical Development: An Open Access Database. WHO; Geneva, Switzerland: 2019.

LinkOut - more resources